Current strategies for modulating sirtuin activity in the treatment of hepatocellular carcinoma (HCC) and non-alcoholic fatty liver disease (NAFLD) focus on the activation and inhibition of specific sirtuins, particularly SIRT1 and SIRT2, respectively. Here, SIRT2 is linked to metabolic dysfunction-associated steatotic liver disease.